Cancer Database Query Results

Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Prostate Cancer, Nutrition, and Dietary Supplements


Scientific Papers found: Click to Expand⟱
9259- Acai, EO,    Antitumor Effect of Açaí (Euterpe oleracea Mart.) Seed Extract in LNCaP Cells and in the Solid Ehrlich Carcinoma Model
- vitro+vivo, Pca, LNCaP
Ingr↝, eff↝, Dose↝, TumVol↓, necrosis↑, IL6↓, IFN-γ↓,
1- Aco,    Recent development on hyperthermia: An effective cotreatment improving radiotherapy outcome
- in-vitro, PC, PANC1 - in-vitro, Pca, DU145
HH↓, PTCH1↓, Bcl-2↓, Gli1↓,
4584- AgNPs,    Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells
- in-vitro, Pca, DU145
selectivity↑, ROS↑, BAX↑, cl‑Casp3↑, p‑PARP↑, TumCCA↑, cycD1/CCND1↓, p27/CDKN1B↑, P21↑, AntiCan↑,
4411- AgNPs,    Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities
- in-vitro, Lung, A549 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, PC3 - in-vitro, Nor, HEK293
AntiCan↑, selectivity↑, Apoptosis↑, TumCCA↑, Bacteria↓, tumCV↓, selectivity↑, Apoptosis↑, TumCCA↑,
4435- AgNPs,  Gluc,    Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
selectivity↑, ROS↑, mtDam↑, TumCCA↑, TumCP↓, Apoptosis↑, MMP↓,
8444- AgNPs,  PBG,    Synthesis of silver nanoparticles reduced by Bingöl propolis and evaluation of antioxidant, anticancer and cytotoxic activities in PC-3 cells
- in-vitro, Pca, PC3
*antiOx↑, TumCP↓, Apoptosis↑, Cyt‑c↑, proCasp3↑,
7426- AgNPs,  CS,    Silver Nanoparticles Formulation of Flower Head's Polyphenols of Cynara scolymus L.: A Promising Candidate against Prostate (PC-3) Cancer Cell Line through Apoptosis Activation
- in-vitro, Pca, PC3 - in-vitro, Lung, A549
*antiOx↑, tumCV↓, eff↑, Dose↝, P53↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓,
318- AgNPs,    Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells
- in-vitro, Pca, PC3
lysoM↓, lysosome↓, AMPKα↑, TumAuto↑, mTOR↑,
392- AgNPs,    Biogenic silver nanoparticles synthesized from Piper longum fruit extract inhibit HIF-1α/VEGF mediated angiogenesis in prostate cancer cells
- in-vitro, Pca, NA
Hif1a↓, VEGF↓,
2646- AL,    Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress
- in-vitro, Pca, DU145 - in-vitro, Melanoma, RPMI-8226
AntiCan↑, eff↓, ChemoSen↑, ER Stress↑, tumCV↓, DNAdam↑, GSH∅, HSP70/HSPA5↓, UPR↑, β-catenin/ZEB1↓, ROS↑, HO-2↑, SIRT1↑, GlucoseCon∅, lactateProd∅, chemoP↑,
3442- ALA,    α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B - in-vitro, Nor, 3T3
tumCV↓, TumCMig↓, TumCI↓, ROS↑, Hif1a↑, JNK↑, Casp↑, TumCCA↑, Apoptosis↑, selectivity↑,
282- ALA,    Alpha-lipoic acid induced apoptosis of PC3 prostate cancer cells through an alteration on mitochondrial membrane depolarization and MMP-9 mRNA expression
- in-vitro, Pca, PC3
MMP↓, Casp↑, MMP9↓,
277- ALA,    α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B
ROS↑, Hif1a↑, JNK↑, Casp3↑, P21↑, BAX↑, Bcl-xL↓, cFos↓,
265- ALA,    Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
ROS↓, SOD↓, GSTP1/GSTπ↓, NRF2↓, p62↓, p62↑, SOD↑, p‑mTOR↑, Beclin-1/ATG6↓, ROS↑, SOD1↑,
6396- ANE,  FEO,    Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
- in-vitro, Pca, PC3
TumCP↓, TumCG↓, TumCMig↓, CSCs↓, ROS↑, MPT↑, Casp3↑, Casp9↑, DNAdam↑, cl‑PARP↑, Bax:Bcl2↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cMyc↓, P21↑, p27/CDKN1B↑, NF-kB↓, eff↑,
1151- Api,    Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study
- in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
TumCCA↑, Apoptosis↑, HDAC↓, P21↑, BAX↑, TumCG↓, Bcl-2↓, Bax:Bcl2↑, HDAC1↓, HDAC3↓,
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, Synergy↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
581- Api,  Cisplatin,    The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy
- in-vitro, Pca, CD44+
Bcl-2↓, survivin↓, Casp8↑, P53↑, Sharpin↓, APAF1↑, p‑Akt↓, NF-kB↓, P21↑, Cyc↓, CDK2↓, CDK4/6↓, Snail↓, ChemoSen↑,
578- Api,  Cisplatin,    Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
- in-vitro, Lung, A549 - in-vitro, BC, MCF7 - in-vitro, CRC, HCT116 - in-vitro, Pca, HeLa - in-vitro, Lung, H1299
p‑P53↑,
5- Api,    Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer
- in-vitro, Pca, NA
HH↓, Gli1↓,
211- Api,    Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice
- in-vivo, Pca, NA
IKKα↓, NF-kB↓, cycD1/CCND1↓, COX2/PTGS2↓, Bcl-2↓, Bcl-xL↓, VEGF↓, PCNA↓, BAX↑,
210- Api,    Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer
- in-vitro, Pca, DU145
EMT↓, E-cadherin↑, Snail↓, Vim↓,
208- Api,    Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancer
- in-vivo, Pca, PC3 - in-vivo, Pca, DU145
XIAP↓, survivin↓, Bcl-xL↓, Bcl-2↓, BAX↑,
207- Api,    Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells
- in-vitro, Pca, LNCaP
PSA↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, P21↑, AR↓,
237- Api,    Apigenin blocks IKKα activation and suppresses prostate cancer progression
- in-vivo, Pca, PC3 - in-vivo, Pca, 22Rv1 - in-vivo, Pca, LNCaP - in-vivo, Pca, DU145
IKKα↓, NF-kB↓,
240- Api,    The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling
- in-vitro, Pca, PC3 - in-vitro, Pca, CD44+
P21↑, p27/CDKN1B↑, Casp3↑, Casp8↑, Slug↓, Snail↓, NF-kB↓, PI3K↓, Akt↓,
238- Api,    Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
VEGF↓, TGF-β↓, Src↓, FAK↓, Akt↓, SMAD2↓, SMAD3↓,
2003- Ash,    Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Nor, TIG-1 - in-vitro, PC, LNCaP
TumCD↑, selectivity↑, cFos↑, ROS↑, *ROS∅, HSP70/HSPA5↑, Apoptosis↑, ER Stress↑, TumCCA↑,
5171- Ash,    The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry"
- vitro+vivo, Pca, LNCaP - vitro+vivo, Pca, PC3
Proteasome↓, BAX↑, p27/CDKN1B↑, AR↓, TumCG↓,
5421- ASTX,    Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice
- in-vivo, Pca, NA
TumCG↑, Ki-67↑, PCNA↓, GutMicro↑, *Inflam↓, *cardioP↑, *ROS↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
147- ATG,  EGCG,  CUR,    Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, MCF7
Bax:Bcl2↑, NF-kB↓, PI3K/Akt↓, STAT3↓, chemoPv↑, TumCP↓, TumCCA↑, TumCMig↓,
6- Ba,  Api,  QC,    Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer
- in-vitro, Pca, PC3
HH↓, Gli1↓,
2479- Ba,    Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
- in-vitro, HCC, SW480 - in-vitro, Pca, PC3
12LOX↓, DR5↑, CHOP/DDIT3↑, ROS↑, *ROS∅, selectivity↑,
2603- Ba,    Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, Apoptosis↑, Cav1↓, p‑Akt↓, p‑mTOR↓, Bax:Bcl2↑, survivin↓, cl‑PARP↑, BioAv↓,
2602- Ba,    Downregulation of ZFX is associated with inhibition of prostate cancer progression by baicalein
- in-vitro, Pca, NA - in-vivo, Pca, NA
ZFX↓, TumCP↓,
1390- BBR,  Rad,    Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells
- in-vitro, Pca, PC3
RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,
1404- BBR,    Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation
- in-vitro, Pca, PC3
Apoptosis↑, *Apoptosis∅, MMP↓, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, ROS↑, eff↓, Cyt‑c↑,
5178- BBR,    Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27/CDKN1B↑, Apoptosis↑, Bax:Bcl2↑, MMP↓, Casp9↑, Casp3↑, PARP↑, DNAdam↑, selectivity↑, Cyt‑c↑,
8- BetA,    Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana
- in-vitro, PC, HaCaT - in-vitro, Pca, PANC1
HH↓, Gli1↓, PTCH1↓, Bcl-2↓,
2754- BetA,    Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors
- in-vitro, Pca, LNCaP
VEGF↓, survivin↓, Sp1/3/4↓, Casp↑, PARP↑, survivin↓, angioG↓,
5597- Bical,    Bicalutamide: clinical pharmacokinetics and metabolism
- Review, Pca, NA
Dose↝, BioAv↑, Half-Life↑, CYP3A4↓, PSA↓,
9206- BITC,    Inhibitory effects of benzyl isothiocyanate on the proliferation of prostate and breast cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
Dose↝, tumCV↓, TumCP↓, eff↝, survivin↓, TGFβR1↓, Casp3↑,
9172- BITC,    Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling
- in-vitro, Pca, PC3
mTOR↓,
9164- BITC,    Benzyl isothiocyanate induces reactive oxygen species-initiated autophagy and apoptosis in human prostate cancer cells
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3
TumCG↓, MMP↓, Casp3↑, Casp7↑, DNAdam↑, ROS↑, eff↓,
9186- BITC,    Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 Arrest
- vitro+vivo, Pca, NA
Dose↝, TumNum↓, Ki-67↓, cycA1/CCNA1↓, cycD1/CCND1↓, CDK2↓, CDK2↓, CDK4↓, TumCCA↓,
9195- BITC,    Benzyl isothiocyanate inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model
- in-vivo, Pca, NA
Dose↑, Ki-67↓, cycE/CCNE↓, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, TumCCA↑,
9185- BITC,  PEITC,  AITC,  ITCs,    Effects of Brassicaceae Isothiocyanates on Prostate Cancer
- Review, Pca, NA
antiOx↑, Inflam↓, Bacteria↓, chemoPv↑, TumCCA↑, Apoptosis↑, ChemoSen↑, TumCP↓, TumCI↓, TumMeta↓, DNMTs↓, HDAC↓, HDAC6↓, AR↓, selectivity↑, CDK1↓, CycB/CCNB1↓, P53↑, WEE1↑, CDC25↓, cMyc↓, cycD1/CCND1↓, cycE/CCNE↓, CDK4↓, CDK6↓, XIAP↓, survivin↓, Bcl-2↓, compIII↓, APAF1↑, ROS↑, OXPHOS↓, MMP↓, Ca+2↑, CXCR4↓, IL6↓, JAK2↓, STAT3↓, mTOR↓, Synergy↑, CSCs↓, uPAR↓, NF-kB↓, TGF-β↓, angioG↓,

Showing Research Papers: 1 to 50 of 461
Page 1 of 10 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 461

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,   NA⇅, 1,   NA↝, 1,   NA?, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 3,   ARE/EpRE↑, 1,   Catalase↓, 2,   Catalase↑, 2,   Copper↓, 1,   Fenton↑, 1,   GCLC↑, 1,   GPx↓, 2,   GPx↑, 4,   GPx4↓, 3,   GSH↓, 13,   GSH↑, 4,   GSH⇅, 1,   GSH↝, 1,   GSH∅, 1,   GSH/GSSG↓, 1,   GSR↓, 2,   GSR↑, 2,   GSTs↑, 1,   H2O2↓, 1,   H2O2↑, 1,   i-H2O2↓, 1,   HO-1↓, 2,   HO-1↑, 5,   HO-2↑, 1,   Iron↑, 4,   Iron↝, 1,   ox-Keap1↓, 1,   rd-Keap1↑, 1,   lipid-P↓, 2,   lipid-P↑, 7,   MDA↓, 2,   MDA↑, 1,   NOX↓, 1,   NQO1↓, 1,   NQO1↑, 4,   NRF2↓, 4,   NRF2↑, 6,   NRF2↝, 1,   NRF2∅, 1,   PrxI∅, 1,   PrxII↑, 1,   PrxII∅, 1,   ROS?, 1,   ROS↓, 9,   ROS↑, 86,   ROS⇅, 4,   ROS↝, 2,   ROS∅, 2,   mt-ROS↑, 1,   SOD↓, 2,   SOD↑, 6,   SOD1↑, 1,   SOD2↓, 1,   TAC↑, 1,   Trx↓, 5,   Trx1↓, 1,   TrxR↓, 2,   TrxR1↓, 1,   xCT/SLC7A11↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↑, 1,   IronCh↑, 1,   IRP1↑, 1,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR↓, 1,   CDC16↓, 1,   CDC25↓, 2,   compIII↓, 1,   EGF↓, 4,   ETC↓, 2,   mitResp↓, 1,   MKP5↑, 1,   mtDam↑, 8,   OCR↓, 1,   OXPHOS↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 2,   5-HETE↓, 1,   5LO↓, 2,   ACC↓, 1,   ACC1↓, 1,   AMACR↓, 1,   AMPK↓, 1,   AMPK↑, 3,   ATP↓, 3,   cAMP⇅, 1,   i-Cer↑, 1,   CholSyn↓, 1,   CPT1A↓, 1,   DHCR24↓, 1,   ECAR↓, 2,   Elvol3↓, 1,   FABP5/E-FABP↓, 1,   FASN↓, 3,   GLO-I↓, 1,   glucose↓, 1,   GlucoseCon↓, 2,   GlucoseCon↑, 1,   GlucoseCon∅, 1,   glut↓, 1,   GlutMet↑, 1,   Glycolysis↓, 10,   GSK‐3β↓, 2,   GSK‐3β↑, 2,   p‑GSK‐3β↓, 2,   HK2↓, 7,   lactateProd↓, 4,   lactateProd∅, 1,   LDHA↓, 5,   NAD↓, 1,   NAD↑, 1,   NADH:NAD↓, 1,   NADPH↓, 4,   NADPH↑, 2,   p‑PCK1↓, 1,   PDK1 / PDPK1↓, 2,   PKM2↓, 5,   p‑PKM2↓, 1,   SIRT1↑, 1,   SREBP1/SREBF1?, 1,   TCA↑, 1,   TumCM/A↑, 1,   Warburg↓, 2,   β-oxidation↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 4,   APAF1↑, 3,   Apoptosis↓, 2,   Apoptosis↑, 115,   Apoptosis↝, 1,   aSmase↝, 1,   autoS↑, 1,   BAD↓, 5,   BAD↑, 4,   BAD↝, 1,   Bak↑, 2,   BAX↓, 2,   BAX↑, 36,   BAX↝, 2,   Bax:Bcl2↑, 13,   Bcl-2↓, 51,   Bcl-2↑, 2,   Bcl-2↝, 1,   Bcl-xL↓, 25,   Bcl-xL↑, 1,   Bcl-xL↝, 1,   BID↑, 3,   BIM↑, 5,   Casp↑, 12,   Casp1↑, 1,   Casp10↑, 1,   Casp12↑, 1,   Casp2↑, 1,   Casp3↓, 2,   Casp3↑, 50,   Casp3↝, 1,   cl‑Casp3↑, 14,   proCasp3↓, 1,   proCasp3↑, 1,   pro‑Casp3↑, 1,   Casp7↑, 9,   Casp8↑, 16,   cl‑Casp8↑, 1,   Casp9↑, 26,   cl‑Casp9↑, 5,   CSR1↑, 1,   Cyt‑c↑, 22,   Cyt‑c↝, 1,   Diablo↑, 3,   DR5↑, 5,   Fas↓, 1,   Fas↑, 2,   FasL↑, 3,   Ferroptosis↓, 1,   Ferroptosis↑, 6,   IAP1↓, 2,   IAP1↑, 1,   ICAD↑, 1,   iNOS↓, 2,   Mcl-1↓, 10,   Mcl-1↑, 1,   MDM2↓, 4,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   necrosis↑, 2,   NOXA↑, 2,   p38↓, 5,   p38↑, 5,   p‑p38↑, 1,   PDCD4↑, 1,   PUMA↑, 3,   PUMA⇅, 1,   Pyro↑, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   survivin↓, 21,   TRAIL↑, 1,   TRAILR↑, 2,   TumCD↓, 2,   TumCD↑, 12,   XIAP?, 1,   XIAP↓, 8,   XIAP↝, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

ABL1↓, 1,   ADCY4↑, 1,   Akt?, 1,   Akt↓, 32,   Akt↑, 1,   Akt↝, 1,   p‑Akt↓, 21,   p‑Akt↑, 1,   AKT1↓, 1,   Akt2↓, 1,   AMPKα↓, 1,   AMPKα↑, 1,   CaMKII ↓, 1,   CDC7↓, 1,   CK2↓, 1,   cMET↓, 2,   CREB↓, 1,   cSrc↓, 1,   DDIT4?, 1,   EGFR↓, 8,   EGFR↝, 1,   p‑EGFR↓, 1,   EphB4↓, 1,   ERK↓, 11,   ERK↑, 2,   p‑ERK↓, 6,   p‑ERK↑, 4,   p‑ERK⇅, 1,   FGFR1↓, 1,   FLT4↓, 1,   FOXD3↑, 1,   HER2/EBBR2↓, 3,   HGF/c-Met↓, 1,   IGF-1R↓, 5,   IKKα↓, 5,   ILK↓, 1,   IκB↓, 2,   IκB↑, 1,   JAK1↓, 2,   JAK2↓, 3,   p‑JAK2↓, 1,   JNK↓, 2,   JNK↑, 8,   JNK↝, 1,   p‑JNK↓, 1,   LIMK1↓, 1,   MAPK↓, 5,   MAPK↑, 5,   p‑MAPK↓, 1,   MEK↓, 1,   MEK↑, 1,   p‑MEK↓, 1,   mTOR↓, 16,   mTOR↑, 1,   mTOR↝, 1,   p‑mTOR↓, 3,   p‑mTOR↑, 1,   mTORC2↓, 1,   NRAS↓, 1,   p‑p42↑, 1,   p70S6↓, 1,   p‑p70S6↓, 1,   P70S6K↓, 2,   P70S6K↑, 1,   PI3K↓, 16,   PI3K↑, 1,   PI3K↝, 1,   p‑PI3K↓, 2,   PI3K/Akt↓, 7,   PI3K/Akt⇅, 1,   PI3k/Akt/mTOR↓, 1,   PI3K/mTOR/ETS2↓, 1,   PKA↓, 1,   PKCδ↓, 1,   p‑PKCδ↓, 1,   PRAS40↓, 1,   PTEN↑, 4,   PTEN↝, 1,   PTK2B / PYK2↓, 1,   Raf↓, 3,   RAS↓, 2,   RTK-RAS↓, 1,   Sp1/3/4↓, 3,   Src↓, 3,   STAT3↓, 20,   p‑STAT3↓, 8,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 1,   ATF4↑, 7,   ATFs↑, 1,   CBP↓, 1,   CBP↑, 2,   cJun↓, 2,   cJun↑, 1,   cMyc↓, 13,   DNMT1↓, 1,   DNMTs↓, 4,   EZH2↓, 2,   FOXO3↑, 1,   p‑FOXO3↓, 1,   GATA3↑, 1,   H3↓, 1,   H3↑, 2,   H3K4↓, 1,   H4↑, 1,   HATs↓, 1,   HDAC↓, 13,   HDAC1↓, 2,   HDAC2↓, 3,   HDAC3↓, 2,   HDAC4↓, 1,   HDAC6↓, 2,   IRF1↑, 1,   Matr↓, 1,   MeCP2↓, 1,   miR-126↓, 1,   miR-129-5p↑, 1,   miR-134↑, 1,   miR-143↑, 1,   miR-148a↓, 1,   miR-155↓, 1,   miR-155↑, 1,   miR-194↑, 1,   miR-19b↓, 1,   miR-200c↓, 1,   miR-205↑, 1,   miR-21↓, 5,   miR-21↑, 2,   miR-210↑, 1,   miR-29b↑, 1,   miR-30a-5p↑, 2,   miR-330-5p↑, 1,   miR-34a↑, 1,   Myc↓, 1,   other?, 1,   other↓, 2,   other↑, 2,   other↝, 21,   PCAF↓, 1,   Prot↓, 1,   SD↑, 1,   SD↝, 1,   Shc↓, 1,   SOX2↓, 1,   SPP1↓, 1,   tumCV↓, 34,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↓, 2,   CHOP/DDIT3↑, 12,   eIF2α↑, 5,   p‑eIF2α↑, 5,   ER Stress↑, 20,   GRP78/BiP↓, 1,   GRP78/BiP↑, 12,   GRP94↑, 1,   Hsc70↓, 1,   HSP27↑, 1,   HSP70/HSPA5↓, 3,   HSP70/HSPA5↑, 2,   HSP72↑, 1,   HSP90↓, 3,   IRE1∅, 1,   NQO2↑, 1,   PDI↑, 1,   PERK↓, 1,   PERK↑, 1,   Proteasome↓, 2,   UPR↑, 5,   XBP-1↑, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   ATG7↑, 1,   Beclin-1/ATG6↓, 1,   Beclin-1/ATG6↑, 3,   LAMP2↓, 1,   LAMP2↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3B↑, 1,   LC3B-II↑, 1,   LC3II↑, 3,   lysoM↓, 1,   lysosome↓, 1,   NEU1↑, 1,   p62↓, 2,   p62↑, 2,   TumAuto↑, 20,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↓, 1,   ATM↑, 1,   ATR↑, 1,   BRCA1↑, 1,   CUL4B↑, 1,   DNA-PK↓, 1,   DNAdam↓, 2,   DNAdam↑, 20,   DNArepair↓, 2,   MSH2↑, 1,   NKX3.1↓, 4,   NKX3.1↑, 1,   P53↓, 2,   P53↑, 17,   P53↝, 1,   p‑P53↑, 3,   PARP↓, 1,   PARP↑, 7,   p‑PARP↑, 3,   cl‑PARP↑, 28,   proPARP↓, 1,   PARP1↓, 1,   PARP1↑, 1,   PCNA↓, 12,   SAPK↑, 1,   TP53↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 7,   CDK1↑, 1,   CDK2↓, 16,   CDK2↑, 3,   CDK4↓, 17,   CDK4↑, 1,   CDK4/6↓, 3,   CDK6↓, 8,   CDK6↑, 1,   Cyc↓, 2,   Cyc↝, 1,   cycA1/CCNA1↓, 3,   CycB/CCNB1↓, 5,   cycD1/CCND1↓, 46,   cycD1/CCND1↝, 1,   cycE/CCNE↓, 12,   cycE1↓, 2,   cycF↓, 1,   E2F4↑, 1,   E2Fs↓, 2,   GADD34↑, 3,   Ki-67↓, 14,   Ki-67↑, 1,   p19↑, 1,   P21↓, 1,   P21↑, 38,   P21↝, 1,   p‑P21↑, 1,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 17,   pRB↓, 2,   pRB↑, 1,   p‑pRB↓, 1,   RB1↑, 3,   cl‑RB1↓, 1,   TAp63α↑, 2,   TumCCA?, 2,   TumCCA↓, 1,   TumCCA↑, 82,   UBE2C↓, 1,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↑, 1,   ALDH1A1↓, 1,   BMP2↓, 1,   BMPs↑, 1,   CD133↓, 3,   cFos↓, 2,   cFos↑, 1,   CSCs↓, 13,   CSCs↑, 1,   Diff↓, 1,   Diff↑, 4,   EP300↑, 1,   FBXW7↝, 1,   FGF↓, 2,   Gli1↓, 10,   HH↓, 14,   HMGCR↓, 1,   Id1↓, 1,   IGF-1↓, 6,   IGF-2↓, 2,   IGFBP3↑, 5,   JAG1↑, 1,   Jun↓, 1,   p‑Jun↓, 1,   p‑Jun↑, 1,   Ki-67↓, 14,   Ki-67↑, 1,   LRP6↓, 1,   mTORC1↓, 3,   Nanog↓, 1,   Neurog1↑, 1,   NF2↑, 1,   NOTCH↓, 2,   NOTCH1↓, 2,   NOTCH3↑, 1,   p300↓, 1,   PCLAF↓, 1,   PTCH1↓, 3,   SCF↓, 1,   Shh↓, 3,   TumCG↓, 94,   TumCG↑, 2,   TumCG∅, 2,   TumCP?, 1,   TumCP↓, 92,   TumCP↑, 2,   TumCP∅, 1,   Wnt↓, 4,   Wnt/(β-catenin)↓, 1,   ZFX↓, 1,  

Migration(tgid=13) ⓘ

ACTA2↓, 1,   AKR1C2↓, 1,   annexin II↓, 1,   AP-1↓, 2,   AP-1↝, 1,   Ca+2↓, 5,   Ca+2↑, 7,   Ca+2↝, 1,   CAFs/TAFs↓, 1,   Cav1↓, 2,   CD38↑, 1,   Cdc42↓, 1,   i-Chl↑, 1,   Cofilin↓, 2,   E-cadherin↓, 2,   E-cadherin↑, 10,   EFEMP↓, 1,   EMT↓, 17,   EpCAM↓, 1,   FAK↓, 4,   GnT-V↝, 1,   heparanase↝, 1,   hnRNPA1↓, 2,   ITGA5↓, 1,   LEF1↓, 2,   MALAT1↓, 1,   MET↑, 1,   MMP2↓, 11,   MMP2↑, 1,   MMP2↝, 1,   MMP7↓, 1,   MMP9↓, 21,   MMP9↑, 1,   MMPs↓, 4,   MUC1↓, 1,   N-cadherin↓, 10,   NM23↑, 1,   p‑p44↑, 1,   PDGF↓, 2,   p‑PDGF↓, 1,   Rac1↓, 1,   Rho↓, 1,   Rho↑, 1,   SDC1↑, 1,   Sharpin↓, 1,   Slug↓, 6,   Smad1↑, 2,   SMAD2↓, 2,   SMAD3↓, 2,   Snail↓, 12,   SPARC↓, 1,   T-cadherin↓, 1,   T-cadherin↑, 1,   TET1↑, 1,   TGF-β↓, 8,   TIMP2↑, 1,   TIMP3↑, 1,   TRIB3↑, 1,   TSC1↑, 1,   TSP-1↑, 2,   TumCA↓, 1,   TumCI?, 1,   TumCI↓, 31,   TumCMig?, 1,   TumCMig↓, 37,   TumMeta↓, 11,   TumMeta∅, 1,   Twist↓, 5,   TXNIP↑, 2,   uPA↓, 6,   uPAR↓, 4,   Vim↓, 10,   Zeb1↓, 1,   β-catenin/ZEB1↓, 14,   β-catenin/ZEB1↝, 1,   p‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 25,   angioG∅, 1,   angioS↑, 1,   CD31/PECAM-1↓, 2,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 13,   Hif1a↑, 3,   VCAM-1↓, 1,   VEGF↓, 31,   VEGF↝, 1,   VEGFR2/KDR/Flk1↓, 6,  

Barriers & Transport(tgid=15) ⓘ

CellMemb↑, 1,   MMP?, 1,   MMP↓, 32,   MMP↑, 1,   MMP↝, 2,   MMP∅, 1,   MPT↑, 3,   NHE1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↓, 1,   CD4+↓, 1,   CD44↓, 4,   CD44↝, 1,   cDC2↓, 3,   COX1?, 1,   COX1↓, 1,   COX2/PTGS2?, 1,   COX2/PTGS2↓, 12,   COX2/PTGS2↝, 1,   CXCc↓, 1,   CXCL1↓, 1,   CXCL12↓, 1,   CXCR4↓, 6,   DR4↑, 1,   FoxP3+↓, 1,   Gal-3?, 1,   Gal-3↓, 1,   HLA-I/II↑, 1,   HMGB1↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 10,   IL6↝, 1,   IL7↓, 1,   Imm↑, 1,   Inflam↓, 7,   MCP1/CCL2↓, 1,   MCT1↓, 1,   Neut↑, 1,   NF-kB↓, 51,   NF-kB↝, 1,   NK cell↑, 1,   NLRP3↓, 1,   p65↓, 5,   p‑p65↓, 1,   ac‑p65↑, 1,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 48,   PSA↝, 1,   RAGE↓, 1,   RANTES↓, 1,   SOCS1↑, 1,   T-Cell↑, 1,   TCF↓, 1,   TLR4↓, 2,   TNF-α↓, 7,   TNF-α↝, 1,   TRADD↑, 1,   TRAF2↑, 1,   VitD↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

PLC↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↝, 1,   AR↓, 48,   AR↑, 1,   AR↝, 4,   AR-FL↓, 1,   AR-V7↑, 1,   COMT↓, 3,   CYP11A1↓, 1,   DHT↓, 2,   ERβ/ESR2↑, 1,   FKBP5↓, 1,   HSD3B↓, 1,   PPARγ↓, 1,   PPARγ↑, 2,   SRD5A1↑, 1,   StAR↓, 1,   testos↓, 2,   testos∅, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 7,   BioAv↑, 11,   BioAv↝, 2,   BioEnh↑, 1,   ChemoSen↑, 33,   ChemoSen↝, 1,   CompStab↓, 1,   CompStab↑, 2,   CYP3A4↓, 1,   Dose?, 4,   Dose↓, 1,   Dose↑, 5,   Dose↝, 62,   Dose∅, 2,   eff↓, 32,   eff↑, 32,   eff↝, 8,   eff∅, 5,   GSTP1/GSTπ↓, 1,   Half-Life↑, 1,   Half-Life↝, 2,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 1,   RadioS?, 1,   RadioS↑, 12,   RadioS∅, 1,   selectivity↓, 2,   selectivity↑, 45,   Synergy↑, 20,  

Clinical Biomarkers(tgid=22) ⓘ

ALP↓, 1,   AR↓, 48,   AR↑, 1,   AR↝, 4,   BRCA1↑, 1,   CEC↝, 1,   CRP↓, 2,   CTC↓, 2,   EGFR↓, 8,   EGFR↝, 1,   p‑EGFR↓, 1,   EZH2↓, 2,   Ferritin↑, 1,   HEC1↓, 1,   HemoG↓, 1,   HER2/EBBR2↓, 3,   IL6↓, 10,   IL6↝, 1,   LDH↓, 1,   LDH↑, 2,   Myc↓, 1,   NOS2↓, 2,   PD-L1↓, 1,   PSA↓, 48,   PSA↝, 1,   PSADT↓, 1,   PSADT↑, 4,   RAGE↓, 1,   TP53↑, 1,   TRIB3↑, 1,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 13,   AntiCan⇅, 1,   AntiDiabetic↑, 1,   antiNeop↑, 4,   AntiTum↓, 1,   AntiTum↑, 4,   cachexia↓, 1,   CardioT↑, 1,   chemoP↑, 7,   chemoPv↑, 16,   ChemoSideEff↓, 1,   CR↑, 1,   IMPDH1↓, 1,   IMPDH2↓, 1,   neuroP↑, 1,   Obesity↓, 2,   Obesity↑, 1,   OS↑, 2,   OS∅, 1,   Pain↓, 3,   Pin1↓, 1,   QoL↝, 1,   radioP?, 1,   radioP↑, 4,   Remission↑, 1,   Risk↓, 26,   Risk↑, 2,   Risk↝, 1,   Risk∅, 5,   TGFβR1↓, 1,   TGFβR1↑, 1,   toxicity↓, 14,   toxicity↑, 1,   toxicity↝, 6,   toxicity∅, 1,   TumNum↓, 1,   TumVol↓, 19,   TumW↓, 9,   Weight↑, 1,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiP↑, 1,   Bacteria↓, 3,   GutMicro↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,   Ingr↑, 1,   Ingr↝, 9,  
Total Targets: 789

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 8,   GSH↑, 1,   GSH/GSSG↑, 1,   ox-Keap1↑, 1,   NRF2↑, 3,   ROS↓, 3,   ROS∅, 3,   SOD↓, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 2,   NADPH∅, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis∅, 1,   Cyt‑c↓, 1,   IAP1↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

JNK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG∅, 1,  

Migration(tgid=13) ⓘ

Ca+2↝, 1,   Ca+2∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1↓, 1,   IL6↓, 1,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 5,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

testos↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   CompStab↑, 1,   Dose↑, 1,   eff↑, 1,   Half-Life↝, 3,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BMD↑, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 1,   AntiCan↑, 2,   cardioP↑, 2,   chemoP↑, 1,   chemoPv↑, 2,   ChemoSideEff↓, 1,   hepatoP↑, 1,   memory↓, 1,   memory↑, 1,   motorD↓, 1,   neuroP↑, 2,   toxicity↓, 12,   toxicity↑, 1,   toxicity↝, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Bacteria↓, 1,  
Total Targets: 57

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page